image
Healthcare - Medical - Instruments & Supplies - NASDAQ - US
$ 0.6866
-7.23 %
$ 4.58 M
Market Cap
-0.21
P/E
1. INTRINSIC VALUE

Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics.[ Read More ]

The intrinsic value of one POAI stock under the base case scenario is HIDDEN Compared to the current market price of 0.687 USD, Predictive Oncology Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart POAI

image
FINANCIALS
1.78 M REVENUE
18.24%
-13.9 M OPERATING INCOME
8.82%
-14 M NET INCOME
45.67%
-13.2 M OPERATING CASH FLOW
-6.62%
-302 K INVESTING CASH FLOW
36.44%
149 K FINANCING CASH FLOW
-97.78%
346 K REVENUE
24.03%
-2.28 M OPERATING INCOME
28.40%
-3.09 M NET INCOME
2.72%
-2.28 M OPERATING CASH FLOW
29.16%
0 INVESTING CASH FLOW
100.00%
888 K FINANCING CASH FLOW
-73.56%
Balance Sheet Decomposition Predictive Oncology Inc.
image
Current Assets 10.1 M
Cash & Short-Term Investments 8.73 M
Receivables 334 K
Other Current Assets 1.02 M
Non-Current Assets 4.34 M
Long-Term Investments 0
PP&E 3.96 M
Other Non-Current Assets 377 K
Current Liabilities 3.95 M
Accounts Payable 1.34 M
Short-Term Debt 668 K
Other Current Liabilities 1.94 M
Non-Current Liabilities 2.19 M
Long-Term Debt 4.38 M
Other Non-Current Liabilities -2.18 M
EFFICIENCY
Earnings Waterfall Predictive Oncology Inc.
image
Revenue 1.78 M
Cost Of Revenue 635 K
Gross Profit 1.15 M
Operating Expenses 15.2 M
Operating Income -13.9 M
Other Expenses 62.6 K
Net Income -14 M
RATIOS
64.34% GROSS MARGIN
64.34%
-782.06% OPERATING MARGIN
-782.06%
-785.58% NET MARGIN
-785.58%
-169.06% ROE
-169.06%
-96.99% ROA
-96.99%
-131.20% ROIC
-131.20%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Predictive Oncology Inc.
image
Net Income -14 M
Depreciation & Amortization 739 K
Capital Expenditures -302 K
Stock-Based Compensation 0
Change in Working Capital -398 K
Others -277 K
Free Cash Flow -13.5 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Predictive Oncology Inc.
image
POAI has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Predictive Oncology Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Sep 25, 2023
Sell 30.4 K USD
Nuzum Charles Lee Sr
Director
- 10000
3.0387 USD
1 year ago
Dec 15, 2022
Bought 2.46 K USD
HANDLEY DANIEL E
Director
+ 6000
0.41 USD
1 year ago
Dec 02, 2022
Bought 5 K USD
MYERS ROBERT L
director: CHIEF FINANCIAL OFFICER
+ 8795
0.5686 USD
1 year ago
Dec 02, 2022
Bought 207 USD
Vennare Raymond F
Director
+ 400
0.5185 USD
1 year ago
Dec 02, 2022
Bought 2.38 K USD
Vennare Raymond F
Director
+ 4600
0.5164 USD
1 year ago
Nov 29, 2022
Bought 3.58 K USD
HANDLEY DANIEL E
Director
+ 10000
0.3578 USD
2 years ago
May 26, 2022
Bought 955 USD
HANDLEY DANIEL E
director:
+ 2550
0.3747 USD
2 years ago
May 25, 2022
Bought 980 USD
HANDLEY DANIEL E
director:
+ 2800
0.35 USD
2 years ago
May 24, 2022
Bought 59.3 K USD
ENGLE J MELVILLE
director:
+ 159500
0.372 USD
2 years ago
May 20, 2022
Bought 62.3 K USD
Nuzum Charles Lee Sr
director:
+ 200000
0.3116 USD
2 years ago
May 20, 2022
Bought 4.89 K USD
MYERS ROBERT L
director: CHIEF FINANCIAL OFFICER
+ 16125
0.3032 USD
4 years ago
Oct 22, 2020
Sell 544 USD
Schwartz Carl I.
Chief Executive Officer
- 640
0.85 USD
4 years ago
Sep 01, 2020
Bought 3.6 K USD
GABRIEL RICHARD L
Director
+ 4000
0.9004 USD
4 years ago
Aug 19, 2020
Bought 3.07 K USD
GABRIEL RICHARD L
Director
+ 2610
1.175 USD
4 years ago
Aug 19, 2020
Bought 460 USD
GABRIEL RICHARD L
Director
+ 390
1.18 USD
5 years ago
Sep 05, 2019
Bought 920 USD
GABRIEL RICHARD L
Director
+ 2000
0.4601 USD
5 years ago
Aug 23, 2019
Bought 496 USD
GABRIEL RICHARD L
Director
+ 800
0.6196 USD
5 years ago
Aug 23, 2019
Bought 1.3 K USD
GABRIEL RICHARD L
Director
+ 2200
0.59 USD
5 years ago
May 24, 2019
Bought 26.7 K USD
Schwartz Carl I.
Chief Executive Officer
+ 48332
0.5522 USD
5 years ago
May 23, 2019
Bought 29.1 K USD
Schwartz Carl I.
Chief Executive Officer
+ 51668
0.5632 USD
5 years ago
Jan 08, 2019
Bought 523 K USD
Schwartz Carl I.
Chief Executive Officer
+ 742188
0.704 USD
5 years ago
Jan 08, 2019
Bought 50 K USD
Schwartz Carl I.
Chief Executive Officer
+ 78125
0.64 USD
5 years ago
Dec 11, 2018
Bought 1.36 K USD
GABRIEL RICHARD L
Director
+ 2000
0.679 USD
5 years ago
Nov 30, 2018
Bought 185 K USD
Schwartz Carl I.
Chief Executive Officer
+ 221292
0.836 USD
5 years ago
Nov 28, 2018
Bought 1.56 K USD
GABRIEL RICHARD L
Director
+ 2000
0.7799 USD
5 years ago
Nov 20, 2018
Bought 890 USD
GABRIEL RICHARD L
Director
+ 1000
0.89 USD
10 years ago
Nov 07, 2014
Bought 4.38 K USD
Herschkowitz Samuel
10 percent owner
+ 500
8.75 USD
10 years ago
Nov 07, 2014
Sell 4.38 K USD
Herschkowitz Samuel
10 percent owner
- 500
8.75 USD
10 years ago
Oct 16, 2014
Bought 3.15 K USD
Herschkowitz Samuel
10 percent owner
+ 25000
0.126 USD
10 years ago
Oct 15, 2014
Bought 11.6 K USD
Herschkowitz Samuel
10 percent owner
+ 105000
0.11 USD
10 years ago
Oct 14, 2014
Bought 6 K USD
Herschkowitz Samuel
10 percent owner
+ 50000
0.12 USD
10 years ago
Oct 03, 2014
Bought 18.7 K USD
Herschkowitz Samuel
10 percent owner
+ 170000
0.11 USD
10 years ago
Oct 02, 2014
Bought 4.47 K USD
Herschkowitz Samuel
10 percent owner
+ 40680
0.11 USD
10 years ago
Sep 15, 2014
Bought 625 USD
MYERS ROBERT L
Chief Financial Officer
+ 5000
0.125 USD
10 years ago
Aug 27, 2014
Bought 2 K USD
JOHNSON DAVID O.
Chief Operating Officer
+ 14300
0.14 USD
10 years ago
Aug 22, 2014
Bought 725 USD
MYERS ROBERT L
Chief Financial Officer
+ 5000
0.145 USD
10 years ago
Aug 19, 2014
Bought 240 USD
Herschkowitz Samuel
10 percent owner
+ 2000
0.12 USD
10 years ago
Jul 23, 2014
Bought 0.15 USD
Kornberg Joshua
CEO and President
+ 1
0.15 USD
10 years ago
Jul 23, 2014
Bought 0.165 USD
Kornberg Joshua
CEO and President
+ 1
0.165 USD
10 years ago
Jul 23, 2014
Bought 0.15 USD
Herschkowitz Samuel
10 percent owner
+ 1
0.15 USD
10 years ago
Jul 23, 2014
Bought 0.165 USD
Herschkowitz Samuel
10 percent owner
+ 1
0.165 USD
10 years ago
Jul 23, 2014
Bought 0.15 USD
SOK Partners LLC
10 percent owner
+ 1
0.15 USD
10 years ago
Jul 23, 2014
Bought 0.165 USD
SOK Partners LLC
10 percent owner
+ 1
0.165 USD
10 years ago
Jul 23, 2014
Bought 3.25 K USD
Herschkowitz Samuel
10 percent owner
+ 25000
0.13 USD
10 years ago
Jul 14, 2014
Bought 806 USD
Herschkowitz Samuel
10 percent owner
+ 6200
0.13 USD
10 years ago
May 22, 2014
Bought 3.5 K USD
Herschkowitz Samuel
10 percent owner
+ 25000
0.14 USD
10 years ago
May 21, 2014
Bought 4.92 K USD
Herschkowitz Samuel
10 percent owner
+ 41000
0.12 USD
10 years ago
Apr 30, 2014
Bought 3.9 K USD
Herschkowitz Samuel
10 percent owner
+ 30000
0.13 USD
10 years ago
Apr 29, 2014
Bought 4.1 K USD
Herschkowitz Samuel
10 percent owner
+ 31500
0.13 USD
10 years ago
Mar 27, 2014
Bought 4.14 K USD
Herschkowitz Samuel
10 percent owner
+ 21812
0.19 USD
10 years ago
Mar 18, 2014
Bought 4.83 K USD
Herschkowitz Samuel
10 percent owner
+ 23000
0.21 USD
10 years ago
Dec 13, 2013
Bought 1.21 K USD
DREYFUSS ARNON I
Director
+ 5021
0.24 USD
10 years ago
Nov 26, 2013
Bought 2.9 K USD
Herschkowitz Samuel
10 percent owner
+ 10000
0.29 USD
10 years ago
Nov 25, 2013
Bought 6.75 K USD
DREYFUSS ARNON I
Director
+ 25000
0.27 USD
11 years ago
Nov 20, 2013
Bought 7.14 K USD
Herschkowitz Samuel
10 percent owner
+ 25500
0.28 USD
11 years ago
Aug 16, 2013
Bought 4.83 K USD
Herschkowitz Samuel
10 percent owner
+ 23000
0.21 USD
11 years ago
Aug 06, 2013
Bought 4.4 K USD
DREYFUSS ARNON I
Director
+ 20000
0.22 USD
11 years ago
Jul 15, 2013
Bought 700 USD
Herschkowitz Samuel
10 percent owner
+ 5000
0.14 USD
11 years ago
Jul 12, 2013
Bought 251 USD
Herschkowitz Samuel
10 percent owner
+ 1933
0.13 USD
11 years ago
Jul 09, 2013
Bought 5.18 K USD
Herschkowitz Samuel
10 percent owner
+ 37000
0.14 USD
11 years ago
Jun 26, 2013
Bought 3.75 K USD
Herschkowitz Samuel
10 percent owner
+ 25000
0.15 USD
11 years ago
May 23, 2013
Bought 4.25 K USD
Herschkowitz Samuel
10 percent owner
+ 25000
0.17 USD
11 years ago
May 15, 2013
Bought 18 K USD
Herschkowitz Samuel
10 percent owner
+ 100000
0.18 USD
11 years ago
May 10, 2013
Bought 5.4 K USD
Herschkowitz Samuel
10 percent owner
+ 30000
0.18 USD
11 years ago
May 07, 2013
Bought 5.1 K USD
Herschkowitz Samuel
10 percent owner
+ 30000
0.17 USD
11 years ago
May 03, 2013
Bought 16.2 K USD
Herschkowitz Samuel
10 percent owner
+ 85000
0.19 USD
11 years ago
Apr 10, 2013
Bought 7.79 K USD
Herschkowitz Samuel
10 percent owner
+ 51940
0.15 USD
11 years ago
Mar 08, 2013
Bought 469 USD
MYERS ROBERT L
Chief Financial Officer
+ 6250
0.075 USD
12 years ago
Jun 25, 2012
Bought 53.6 K USD
Caron Partners LP
10 percent owner
+ 357143
0.15 USD
12 years ago
Jun 25, 2012
Bought 25 K USD
Caron Partners LP
10 percent owner
+ 357143
0.07 USD
7. News
Predictive Oncology Reports Third Quarter 2024 Financial Results and Provides Strategic Update Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value Company initiates process to explore a broad range of strategic alternatives to maximize shareholder value globenewswire.com - 4 days ago
Predictive Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference PITTSBURGH, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, is scheduled to deliver a virtual presentation and host investor one-on-one meetings at the H.C. Wainwright 26th Annual Global Investment Conference, which is being held September 9th through 11th in New York, NY. globenewswire.com - 2 months ago
Predictive Oncology Inc. (POAI) Q2 2024 Earnings Call Transcript Predictive Oncology Inc. (NASDAQ:POAI ) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Glenn Garmont – Investor Relations Raymond Vennare – Chairman and Chief Executive Officer Josh Blacher – Chief Financial Officer Conference Call Participants Operator Good day, and thank you for standing by. Welcome to the Predictive Oncology Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Predictive Oncology Reports Second Quarter 2024 Financial Results and Provides Business Update Company to host investor call and webcast today, August 14th, at 8:30am EDT Company to host investor call and webcast today, August 14th, at 8:30am EDT globenewswire.com - 3 months ago
Predictive Oncology to Report Second Quarter 2024 Financial Results on Wednesday, August 14, 2024 PITTSBURGH, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments (CLIA) laboratory and Good Manufacturing Practices (GMP) facility, to accelerate oncology drug discovery and enable drug development, today announced that it will report its financial results for the second quarter ended June 30, 2024 before the markets open on Wednesday, August 14, 2024. The company will host a corporate update conference call and live audio webcast at 8:30 a.m. globenewswire.com - 3 months ago
Predictive Oncology Announces Exercise of Warrants for $1.26 Million Gross Proceeds PITTSBURGH, July 26, 2024 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that it has entered into a definitive agreement for the exercise of certain existing warrants to purchase an aggregate of 958,117 shares of its common stock having a current exercise price of $14.00 originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share. The issuance and/or resale of the shares of common stock issuable upon exercise of the existing warrants, as applicable, are registered pursuant to effective registration statements on Form S-1 (File No. 333-267689), Form S-3 (File No. 254309) and Form S-3 (333-255582). The gross proceeds to Predictive Oncology from the exercise of the existing warrants are expected to be approximately $1.26 million, prior to deducting placement agent fees and transaction expenses payable by the Company. globenewswire.com - 3 months ago
Why Is Predictive Oncology (POAI) Stock Up 70% Today? Shares of biotechnology specialist Predictive Oncology (NASDAQ: POAI ) — which leverages artificial intelligence (AI) and machine learning models for the discovery of novel biomarkers in cancer research protocols — soared on Thursday. Earlier, the company announced a major development in terms of the predictability models of ovarian cancer. investorplace.com - 3 months ago
Predictive Oncology Enters Biomarker Discovery Market After Successful Retrospective Ovarian Cancer Study Yields Compelling Results Expands AI/ML driven offering to include novel oncology biomarker discovery to predict patient outcomes and drug response in oncology globenewswire.com - 3 months ago
Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs) Company files expansive intellectual property protection for “Membrane Protein Factory” to produce purified and biologically active membrane proteins for drug development globenewswire.com - 5 months ago
Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery Predictive Oncology's organ-specific in vitro models are designed to better mimic  the physiological environment of human tissue globenewswire.com - 5 months ago
Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024 Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery Presentation to highlight Company's novel application of AI/machine learning capabilities utilizing its proprietary biobank of more than 150,000 tumor samples to guide leading biopharma partners through early oncologic drug discovery globenewswire.com - 5 months ago
Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone Study successfully demonstrated Predictive's ability to build AI multi-omic machine learning models to predict survival outcomes among ovarian cancer patients better than clinical data alone globenewswire.com - 5 months ago
8. Profile Summary

Predictive Oncology Inc. POAI

image
COUNTRY US
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 4.58 M
Dividend Yield 0.00%
Description Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
Contact 2915 Commers Drive, Eagan, MN, 55121 https://www.predictive-oncology.com
IPO Date May 3, 2010
Employees 34
Officers Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D. Senior Vice President of Biologics Mr. Joshua Blacher M.B.A. Interim Chief Financial Officer Dr. Arlette H. Uihlein FCAP, M.D. Senior Vice President of Translational Medicine & Drug Discovery and Medical Director Mr. Raymond F. Vennare Chief Executive Officer & Chairman Ms. Theresa Ferguson Senior Director of Marketing